Sandbox:Shalinder: Difference between revisions

	Xyz Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Xyz from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Sandbox:Shalinder On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Sandbox:Shalinder All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Sandbox:Shalinder
CDC on Sandbox:Shalinder
Sandbox:Shalinder in the news
Blogs on Sandbox:Shalinder
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Sandbox:Shalinder

← Older edit Newer edit →

VisualWikitext

Revision as of 14:08, 4 October 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Medical Therapy

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Disease Name

1 Stage 1 - Name of stage
- 1.1 Specific Organ system involved 1
  - 1.1.1 Adult
    - Preferred regimen (1): drug name 100 mg PO q12h for 10-21 days (Contraindications/specific instructions)
    - Preferred regimen (2): drug name 500 mg PO q8h for 14-21 days
    - Preferred regimen (3): drug name 500 mg q12h for 14-21 days
    - Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
    - Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
    - Alternative regimen (3): drug name 500 mg PO q6h for 14–21 days
  - 1.1.2 Pediatric
    - 1.1.2.1 (Specific population e.g. children < 8 years of age)
      - Preferred regimen (1): drug name 50 mg/kg PO per day q8h (maximum, 500 mg per dose)
      - Preferred regimen (2): drug name 30 mg/kg PO per day in 2 divided doses (maximum, 500 mg per dose)
      - Alternative regimen (1): drug name10 mg/kg PO q6h (maximum, 500 mg per day)
      - Alternative regimen (2): drug name 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
      - Alternative regimen (3): drug name 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
    - 1.1.2.2 (Specific population e.g. 'children < 8 years of age')
      - Preferred regimen (1): drug name 4 mg/kg/day PO q12h（maximum, 100 mg per dose）
      - Alternative regimen (1): drug name 10 mg/kg PO q6h (maximum, 500 mg per day)
      - Alternative regimen (2): drug name 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
      - Alternative regimen (3): drug name 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
- 1.2 Specific Organ system involved 2
  - 1.2.1 Adult
    - Preferred regimen (1): drug name 500 mg PO q8h
  - 1.2.2 Pediatric
    - Preferred regimen (1): drug name 50 mg/kg/day PO q8h (maximum, 500 mg per dose)

2 Stage 2 - Name of stage
- 2.1 Specific Organ system involved 1
  Note (1):
  
  Note (2):
  
  Note (3):
  - 2.1.1 Adult
    - Parenteral regimen
      - Preferred regimen (1): drug name 2 g IV q24h for 14 (14–21) days
      - Alternative regimen (1): drug name 2 g IV q8h for 14 (14–21) days
      - Alternative regimen (2): drug name 18–24 MU/day IV q4h for 14 (14–21) days
    - Oral regimen
      - Preferred regimen (1): drug name 500 mg PO q8h for 14 (14–21) days
      - Preferred regimen (2): drug name 100 mg PO q12h for 14 (14–21) days
      - Preferred regimen (3): drug name 500 mg PO q12h for 14 (14–21) days
      - Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
      - Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
      - Alternative regimen (3):drug name 500 mg PO q6h for 14–21 days
  - 2.1.2 Pediatric
    - Parenteral regimen
      - Preferred regimen (1): drug name 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
      - Alternative regimen (1): drug name 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
      - Alternative regimen (2): drug name 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day) '(Contraindications/specific instructions)'
    - Oral regimen
      - Preferred regimen (1): drug name 50 mg/kg/day PO q8h for 14 (14–21) days (maximum, 500 mg per dose)
      - Preferred regimen (2): drug name (for children aged ≥ 8 years) 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
      - Preferred regimen (3): drug name 30 mg/kg/day PO q12h for 14 (14–21) days (maximum, 500 mg per dose)
      - Alternative regimen (1): drug name 10 mg/kg PO q6h 7–10 days (maximum, 500 mg per day)
      - Alternative regimen (2): drug name 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose)
      - Alternative regimen (3): drug name 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose)
- 2.2 'Other Organ system involved 2'
  Note (1):
  
  Note (2):
  
  Note (3):
  - 2.2.1 Adult
    - Parenteral regimen
      - Preferred regimen (1): drug name 2 g IV q24h for 14 (14–21) days
      - Alternative regimen (1): drug name 2 g IV q8h for 14 (14–21) days
      - Alternative regimen (2): drug name 18–24 MU/day IV q4h for 14 (14–21) days
    - Oral regimen
      - Preferred regimen (1): drug name 500 mg PO q8h for 14 (14–21) days
      - Preferred regimen (2): drug name 100 mg PO q12h for 14 (14–21) days
      - Preferred regimen (3): drug name 500 mg PO q12h for 14 (14–21) days
      - Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
      - Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
      - Alternative regimen (3):drug name 500 mg PO q6h for 14–21 days
  - 2.2.2 Pediatric
    - Parenteral regimen
      - Preferred regimen (1): drug name 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
      - Alternative regimen (1): drug name 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
      - Alternative regimen (2): drug name 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day)
    - Oral regimen
      - Preferred regimen (1): drug name 50 mg/kg/day PO q8h for 14 (14–21) days (maximum, 500 mg per dose)
      - Preferred regimen (2): drug name 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
      - Preferred regimen (3): drug name 30 mg/kg/day PO q12h for 14 (14–21) days (maximum, 500 mg per dose)
      - Alternative regimen (1): drug name 10 mg/kg PO q6h 7–10 days (maximum, 500 mg per day)
      - Alternative regimen (2): drug name 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose)
      - Alternative regimen (3): drug name 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose)

References

Template:WH Template:WS

@@ Line 1: / Line 1: @@
 __NOTOC__
+{{Xyz}}
+{{CMG}}; {{AE}}
-{{CMG}}; {{AE}} {{S.S}}
+==Overview==
+There is no treatment for [disease name]; the mainstay of therapy is supportive care.
-==Overview==
+OR
-Atopic dermatitis is a chronic or relapsing hypersensitive manifestation of the skin. Common physical examination findings of atopic dermatitis include pruritus, eczematous lesions, xerosis and lichenification. The lesions are usually age specific and can be in various stages of development. The lesions can involve any area of body in severe cases, but usually it is uncommon to find lesions in  the axillary, gluteal, or groin area.
+Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].
+OR
+The majority of cases of [disease name] are self-limited and require only supportive care.
+OR
+[Disease name] is a medical emergency and requires prompt treatment.
+OR
+The mainstay of treatment for [disease name] is [therapy].
-==Physical Examination==
+OR
-The clinical presentation of atopic dermatitis is highly variable, depending upon the patient's age and disease activity.
+The optimal therapy for [malignancy name] depends on the stage at diagnosis.
-===Appearance of the Patient===
+OR
-*Patients with atopic dermatitis usually appear normal.
-===Vital Signs===
+[Therapy] is recommended among all patients who develop [disease name].
-*Vitals signs in atopic dermatitis patients are usually within normal limits.
+OR
-===Skin===
+Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
-* '''Primary findings''':<ref name="Thestrup-Pedersen2000">{{cite journal|last1=Thestrup-Pedersen|first1=K.|title=Clinical aspects of atopic dermatitis|journal=Clinical and Experimental Dermatology|volume=25|issue=7|year=2000|pages=535–543|issn=0307-6938|doi=10.1046/j.1365-2230.2000.00696.x}}</ref>
-** Atopic Itch: Severe pruritus- cardinal feature of atopic dermatitis (must be present)
-** Atopic dry skin: xerosis (especially during winters)
-** Atopic eczema: location of lesions has age-specific patterns
-** Stigmata of AD
-* Constant scratching may lead to lichenification.
-* An acute eczematoid eruption (with erythematous papules) appears after patients scratch their skin
-* Most severe form of atopic dermatitis can include erythroderma
-* '''Typical morphology and distribution''':<ref>{{cite journal|title=Japanese Dermatological Association Criteria for the diagnosis of atopic dermatitis|journal=The Journal of Dermatology|volume=29|issue=6|year=2002|pages=398–398|issn=03852407|doi=10.1111/j.1346-8138.2002.tb00292.x}}</ref>
-** Eczematous dermatitis: Symmetrical lesions
-{| class="wikitable"
-|+
-!'''Acute atopic dermatitis'''
-!'''Subacute or chronic atopic dermatitis''':
-|-
-|
-* Erythema, exudates, papules, vesicles, scales and crusts
-* Can usually get  infected with ''Staphylococcus aureus''
-* Lesions are intensely pruritic
-|
-* Infiltrated erythema, prurigo, scales and crusts
-* Lesions are dry or excoriated erythematous papules
-* Lichenification (chronic scratching may result in skin thickening) and fissuring may develop over time
-|}
-*'''Age-specific patterns''':<ref name="pmid97349034">{{cite journal |vauthors=Rudikoff D, Lebwohl M |title=Atopic dermatitis |journal=Lancet |volume=351 |issue=9117 |pages=1715–21 |date=June 1998 |pmid=9734903 |doi=10.1016/S0140-6736(97)12082-7 |url=}}</ref>
-{| class="wikitable"
-|+
-!'''Infants and young children(zero to two years)'''
-|-
-|
-* Earliest lesions:
-** Presents with erythema and exudation of the creases(antecubital and popliteal fossae)
-* Over the following few weeks:
+OR
-** highly pruritic, red, scaly and crusted lesions, usually localized to the cheeks, the forehead and scalp, and the extensors of the lower legs
-* Lesions are ill-defined, erythematous, scaly, and crusted (eczematous) patches and plaques.
-* The most commonly involved areas:
-** Scalp, cheeks and extensor side of the extremities.
-** Flexural areas, especially the neck fold, may be involved
-* Midline of the face and the tip of the nose is spared (Yamamoto’s sign)
-* Diaper area is generally spared
-* Lichenification is uncommon in infancy
-|-
-!'''Older children and adolescents (2 to 16 years)'''
-|-
-|
-* Lichenification is characteristic of childhood atopic dermatitis
-* Areas involved:
+Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
-** Flexural areas, particularly the antecubital and popliteal fossae, and buttock-thigh creases
-** Volar aspect of the wrists and ankles may be involved
-** "Atopic dirty neck" - neck and sides of the neck may show a reticulate pigmentation
-* Thickened plaques show lichenification and excoriation
-* Xerosis is generalized
-* Dennie-Morgan folds (i.e. increased folds below the eye) along with erythema and scaling around the eyes is often seen
-* Centrofacial pallor is common
-* Dry skin and fissuring behind the ears or on the earlobe (infra-auricular and retroauricular fissuring)
-* In African-American children, follicular papular lesions are prominent and striking and hypopigmentation and hyperpigmentation
-|-
-!'''Adults (from puberty onward)'''<ref name="pmid18402293">{{cite journal |vauthors=Kulthanan K, Samutrapong P, Jiamton S, Tuchinda P |title=Adult-onset atopic dermatitis: a cross-sectional study of natural history and clinical manifestation |journal=Asian Pac. J. Allergy Immunol. |volume=25 |issue=4 |pages=207–14 |date=December 2007 |pmid=18402293 |doi= |url=}}</ref>
-|-
-|
-* Lesions are more localized and lichenified.
-* Areas involved:
-** Facial involvement is common, especially the forehead and periorbital regions.
-** Lichenification occurs in skin flexures such as wrists, hands, ankles, feet, fingers, and toes
-* A brown macular ring around the neck may be present (localized deposition of amyloid)- "Atopic dirty neck"
+OR
-* Xerosis is prominent
-|}
-* '''Associated symptoms with atopic dermatitis''':<ref name="RotheGrant-Kels19963">{{cite journal|last1=Rothe|first1=Marti Jill|last2=Grant-Kels|first2=Jane M|title=Diagnostic criteria for atopic dermatitis|journal=The Lancet|volume=348|issue=9030|year=1996|pages=769–770|issn=01406736|doi=10.1016/S0140-6736(05)65206-3}}</ref>
-{| class="wikitable"
-|+
-!'''Atopic stigmata'''
-(associated cutaneous findings seen in atopic dermatitis patients)
-|-
-|
-* Atypical vascular responses
-** Centrofacial pallor
-** delayed blanch response
-* Skin
-** Keratosis pilaris
-** Palmar hyperlinearity
-** Pityriasis alba
-** ichthyosis
-* Ocular/periorbital
-** Periorbital darkening and Dennie-Morgan infraorbital folds
-** Hertoghe's sign- thinning or absence of the lateral portion of the eyebrows
-* Other
-** Infra-auricular and retro-auricular fissuring
-** Nipple eczema
-** White dermographism
-** Perifollicular accentuation
-|-
-|
-|}
-* '''Clinical phenotypes of atopic dermatitis:'''
-** Localized and morphological variants of atopic dermatitis are present in both children and adults.
-** These variants can present as only clinical feature of atopic dermatitis or can present in association with age related manifestations.
-{| class="wikitable"
+Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
-|+
-! colspan="2" |Different phenotypes of atopic dermatitis<ref name="pmid21054785">{{cite journal |vauthors=Pugliarello S, Cozzi A, Gisondi P, Girolomoni G |title=Phenotypes of atopic dermatitis |journal=J Dtsch Dermatol Ges |volume=9 |issue=1 |pages=12–20 |date=January 2011 |pmid=21054785 |doi=10.1111/j.1610-0387.2010.07508.x |url=}}</ref>
-|-
-| colspan="2" |
-* Acute vs chronic eczema
-* Intrinsic vs extrinsic atopic eczema
-* Early onset vs late onset
-* Mild vs severe eczema
-* Increased IgE vs non-atopic
-* S. aureus infection/colonization, disseminated viral or fungal infections e.g. EH, molluscum contagiosum, Malassezia
-* Associated with ichthyosis, keratosis pilaris, palmar hyperlinearity, early onset, severe and persistent eczema (FLG null genotype)
-|-
-!Localized variants
-!Morphological variants
-|-
-|
-* Hand eczema
-* Juvenile palmar and plantar dermatitis
-* Eyelid dermatitis
-* Atopic cheilitis
-* Periorificial dermatitis
-* Nipple dermatitis
-|
-* Nummular eczema
-* Atopic prurigo
+OR
-* Lichen planus-like
+Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
-* Pit<span class="_ _1 current-selection"></span>yriasis alba<span class="_ _1 current-selection"></span>
+==Medical Therapy==
-|}
+*Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
-* '''Localized variants''':<ref name="pmid21054785" />
+*Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
-** Atopic hand eczema:<ref name="pmid16956463">{{cite journal |vauthors=Simpson EL, Thompson MM, Hanifin JM |title=Prevalence and morphology of hand eczema in patients with atopic dermatitis |journal=Dermatitis |volume=17 |issue=3 |pages=123–7 |date=September 2006 |pmid=16956463 |doi= |url=}}</ref>
+*Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
-*** Atopic hand eczema typically affects volar wrists and dorsum of the hands.
+*Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
-*** one-third of patients with atopic hand eczema, also reports foot eczema.<ref name="pmid25716740">{{cite journal |vauthors=Brans R, Hübner A, Gediga G, John SM |title=Prevalence of foot eczema and associated occupational and non-occupational factors in patients with hand eczema |journal=Contact Derm. |volume=73 |issue=2 |pages=100–7 |date=August 2015 |pmid=25716740 |doi=10.1111/cod.12370 |url=}}</ref>
+===Disease Name===
-*** Common in adults with past medical history of history of atopic dermatitis, and currently do not have dermatitis in typical areas (i.e. flexural)
-*** Most common in adults exposed to wet environments
-** Eyelid eczema:<ref name="pmid24314387">{{cite journal |vauthors=Wolf R, Orion E, Tüzün Y |title=Periorbital (eyelid) dermatides |journal=Clin. Dermatol. |volume=32 |issue=1 |pages=131–40 |date=2014 |pmid=24314387 |doi=10.1016/j.clindermatol.2013.05.035 |url=}}</ref>
-*** Some patients of atopic dermatitis, may present with eyelid eczema alone
-*** associated with lichenification and presence of Dennie-Morgan lines
-** Atopic cheilitis:
-*** Also known as lip eczema or cheilitis sicca
-*** Presents as dryness, peeling, and fissuring of the lips
-** Juvenile papular dermatitis:<ref name="pmid83084">{{cite journal |vauthors=Rasmussen JE |title=Sutton's summer prurigo of the elbows |journal=Acta Derm. Venereol. |volume=58 |issue=6 |pages=547–9 |date=1978 |pmid=83084 |doi= |url=}}</ref>
-*** Primarily occurs in the spring and summer - associated with pollinosis
-*** localized mainly to the elbows and knees
-** Juvenile palmar and plantar dermatitis
-*** painful variant of atopic dermatitis
-*** Localized on the anterior part of the sole
-* '''Morphological variants''':<ref name="pmid21054785" />
-** Nummular (discoid eczema):
-*** Sharply demarcated patches and plaques with inflammation of skin
-*** Secondarily infection with Staphylococcus aureus common
-*** Commonly affected areas- extremities and buttocks
-*** Very difficult to treat
-=== HEENT ===
+* '''1 Stage 1 - Name of stage'''
-* HEENT examination of patients with atopic dermatitis is usually normal.
+** 1.1 '''Specific Organ system involved 1'''
+*** 1.1.1 '''Adult'''
+**** Preferred regimen (1): [[drug name]] 100 mg PO q12h for 10-21 days '''(Contraindications/specific instructions)'''
+**** Preferred regimen (2): [[drug name]] 500 mg PO q8h for 14-21 days
+**** Preferred regimen (3): [[drug name]] 500 mg q12h for 14-21 days
+**** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days
+**** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
+**** Alternative regimen (3): [[drug name]] 500 mg PO q6h for 14–21 days
+*** 1.1.2 '''Pediatric'''
+**** 1.1.2.1 (Specific population e.g. '''children < 8 years of age''')
+***** Preferred regimen (1): [[drug name]] 50 mg/kg PO per day q8h (maximum, 500 mg per dose)
+***** Preferred regimen (2): [[drug name]] 30 mg/kg PO per day in 2 divided doses (maximum, 500 mg per dose)
+***** Alternative regimen (1): [[drug name]]10 mg/kg PO q6h (maximum, 500 mg per day)
+***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
+***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
+****1.1.2.2 (Specific population e.g. '<nowiki/>'''''children < 8 years of age'''''')
+***** Preferred regimen (1): [[drug name]] 4 mg/kg/day PO q12h（maximum, 100 mg per dose）
+***** Alternative regimen (1): [[drug name]] 10 mg/kg PO q6h (maximum, 500 mg per day)
+***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
+***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
+** 1.2 '''Specific Organ system involved 2'''
+*** 1.2.1 '''Adult'''
+**** Preferred regimen (1): [[drug name]] 500 mg PO q8h
+*** 1.2.2  '''Pediatric'''
+**** Preferred regimen (1): [[drug name]] 50 mg/kg/day PO q8h (maximum, 500 mg per dose)
-* Eczematous lesions can be present depending on the age of the patients.
+* 2 '''Stage 2 - Name of stage'''
+** 2.1 '''Specific Organ system involved 1 '''
+**: '''Note (1):'''
+**: '''Note (2)''':
+**: '''Note (3):'''
+*** 2.1.1 '''Adult'''
+**** Parenteral regimen
+***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
+***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
+***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
+**** Oral regimen
+***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
+***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
+***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
+***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days
+***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
+***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
+*** 2.1.2 '''Pediatric'''
+**** Parenteral regimen
+***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
+***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
+***** Alternative regimen (2):  [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day) '<nowiki/>'''''(Contraindications/specific instructions)''''''
+**** Oral regimen
+***** Preferred regimen (1):  [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days  (maximum, 500 mg per dose)
+***** Preferred regimen (2): [[drug name]] '''(for children aged ≥ 8 years)''' 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
+***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days  (maximum, 500 mg per dose)
+***** Alternative regimen (1):  [[drug name]] 10 mg/kg PO q6h 7–10 days  (maximum, 500 mg per day)
+***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days  (maximum, 500 mg per dose)
+***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days  (maximum,500 mg per dose)
+** 2.2  '<nowiki/>'''''Other Organ system involved 2''''''
+**: '''Note (1):'''
+**: '''Note (2)''':
+**: '''Note (3):'''
+*** 2.2.1 '''Adult'''
+**** Parenteral regimen
+***** Preferred regimen (1): [[drug name]] 2 g IV q24h for 14 (14–21) days
+***** Alternative regimen (1): [[drug name]] 2 g IV q8h for 14 (14–21) days
+***** Alternative regimen (2): [[drug name]] 18–24 MU/day IV q4h for 14 (14–21) days
+**** Oral regimen
+***** Preferred regimen (1): [[drug name]] 500 mg PO q8h for 14 (14–21) days
+***** Preferred regimen (2): [[drug name]] 100 mg PO q12h for 14 (14–21) days
+***** Preferred regimen (3): [[drug name]] 500 mg PO q12h for 14 (14–21) days
+***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days
+***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
+***** Alternative regimen (3):[[drug name]] 500 mg PO q6h for 14–21 days
+*** 2.2.2 '''Pediatric'''
+**** Parenteral regimen
+***** Preferred regimen (1): [[drug name]] 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
+***** Alternative regimen (1): [[drug name]] 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
+***** Alternative regimen (2):  [[drug name]] 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day)
+**** Oral regimen
+***** Preferred regimen (1):  [[drug name]] 50 mg/kg/day PO q8h for 14 (14–21) days  (maximum, 500 mg per dose)
+***** Preferred regimen (2): [[drug name]] 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
+***** Preferred regimen (3): [[drug name]] 30 mg/kg/day PO q12h for 14 (14–21) days  (maximum, 500 mg per dose)
+***** Alternative regimen (1):  [[drug name]] 10 mg/kg PO q6h 7–10 days  (maximum, 500 mg per day)
+***** Alternative regimen (2): [[drug name]] 7.5 mg/kg PO q12h for 14–21 days  (maximum, 500 mg per dose)
+***** Alternative regimen (3): [[drug name]] 12.5 mg/kg PO q6h for 14–21 days  (maximum,500 mg per dose)
-===Neck===
-* Neck examination of patients with atopic dermatitis is usually normal.
-* Eczematous lesions can be present depending on the age of the patients.
-===Lungs===
-* Pulmonary examination of patients with atopic dermatitis is usually normal.
-===Heart===
-* Cardiovascular examination of patients with atopic dermatitis is usually normal.
-===Abdomen===
-* Abdominal examination of patients with atopic dermatitis is usually normal.
-===Back===
-* Back examination of patients with atopic dermatitis is usually normal.
-* Eczematous lesions can be present depending on the age of the patients.
-===Genitourinary===
-* Genitourinary examination of patients with atopic dermatitis is usually normal.
-===Neuromuscular===
-* Neuromuscular examination of patients with atopic dermatitis is usually normal.
-===Extremities===
-* Extremities examination of patients with atopic dermatitis is usually normal.
-* Eczematous lesions can be present depending on the age of the patients.
 ==References==
 {{Reflist|2}}